



because every woman deserves to be sure

About half of all women have dense breast tissue.

This means they're about 5-times more likely to develop breast cancer in their lifetime. And because dense breast tissue camouflages cancer tissue on a mammogram — as much as 52% in very fibrous breasts — these women are also less likely to receive a potentially life-saving early diagnosis. Every woman deserves access to early detection.

That's why we developed Syantra DX | Breast Cancer.



a blood test for breast cancer

Syantra DX | Breast Cancer

Syantra DX is a diagnostic procedure that uses a routine blood test, standard lab equipment and our proprietary data analysis software to detect breast cancer.

As a blood-based test, Syantra DX provides a rapid, economical, accurate method of breast cancer screening for any woman. There's no exposure to radiation, no uncomfortable procedures and the test is effective regardless of the patient's breast tissue density.

Syantra DX has returned a 92% accuracy rate from over 738 pre-biopsy samples examined.

The go-forward plan for Syantra DX

Early diagnosis saves lives. That reality has been the driver behind our focus on being market-ready from day one. Here are some of the ways we've pursued that:


1) **Regulatory compliance** – From the outset, we took steps to ensure that once authenticated, our data validation program would be compliant with major regulatory requirements around the world.

2) **Suppliers** – Our supply chain is global and well defined. From software to blood tubes and qPCR instruments, we have agreements in place to ensure that when ready, Syantra DX can be deployed around the world.

3) **Business model** – Syantra DX's simple, five-step process (below) makes it easy to deploy and uniquely suited to delivery in diagnostic labs. We have conceived of a model where partner labs can execute steps one, two, three and five. Syantra Inc. conducts step four: quality control and data analysis. Syantra provides necessary equipment to partner labs and ensures access to blood collection tubes.

Next steps for Syantra DX

We are currently engaged in clinical studies in Manchester, UK, Calgary, Canada and Oklahoma City, USA and are poised to begin work in Seoul, South Korea. Our goal is to get initial implementation within the UK during the second quarter of 2020.



Who is Syantra Inc.?

Syantra is a privately held company from Calgary, Alberta. Our exceptional, multidisciplinary team is comprised of clinicians, bioengineers, data scientists, laboratory scientists, regulatory experts and business development professionals.

Syantra Inc.
125B – 50 Collegiate Place NW
Calgary, AB
T2N 1N4 Canada
syantra.com

Key partners & associates:

Manchester University
NHS Foundation Trust (UK)
NorthWest EHealth (UK)
University of Calgary (Canada)
Alberta Cancer Foundation (Canada)
Alberta Innovates (Canada)
DynalIFE Medical Labs (Canada)
Yonsei University (South Korea)

Contact us:

Bob Shepherd
President & CEO
bob.shepherd@syantra.com
T. +1 403 629 4404

Terry Macartney
Vice President Business Development
terry.macartney@syantra.com
T. +1 403 560 1714

